Regulus Therapeutics Inc (RGLS) — Capital Reinvestment Ratio

Latest as of December 2020: 0.07x

Regulus Therapeutics Inc (RGLS) has a Capital Reinvestment Ratio of 0.07x as of December 2020, meaning it reinvests 0% of its operating cash flow ($3.19 Million) in capital expenditures ($237.00K). See Regulus Therapeutics Inc balance sheet independence to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

0.07x
Capex / Operating Cash Flow

Operating Cash Flow

$3.19 Million
USD

Capital Expenditures

$237.00K
USD

Data as of

Dec 2020
Most recent filing

Regulus Therapeutics Inc Capital Reinvestment Ratio (2010–2010)

This chart tracks Regulus Therapeutics Inc's Capital Reinvestment Ratio across 1 annual periods. Check how aggressively does Regulus Therapeutics Inc reinvest cash to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for Regulus Therapeutics Inc (2010–2010)

Year-by-year Capital Reinvestment Ratio for Regulus Therapeutics Inc from 2010 to 2010. For live market cap and broader valuation context, see RGLS stock market capitalisation.

Year Reinvestment Ratio Operating CF (USD) Capital Expenditures YoY Change
2010 0.20x $12.31 Million $2.42 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow